NASDAQ:PAVMPAVmed Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding PAVmed Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.02 -0.01 (-0.49 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$2.01Now: $2.02▼$2.1850-Day Range$1.94MA: $2.13▼$2.4452-Week Range$0.81Now: $2.02▼$3.45Volume915,100 shsAverage Volume1.16 million shsMarket Capitalization$95.88 millionP/E RatioN/ADividend YieldN/ABeta-0.01 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingPAVmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, PAVmed has a potential upside of 147.5% from its current price of $2.02.Amount of Analyst CoveragePAVmed has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesPAVmed has received 191 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPAVmed has received 173 “underperform” votes. (Add your “underperform” vote.)Community SentimentPAVmed has received 52.47% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about PAVmed and other stocks. Vote “Outperform” if you believe PAVM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PAVM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPAVmed does not currently pay a dividend.Dividend GrowthPAVmed does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PAVmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $143,868.00 in company stock.Percentage Held by InsidersOnly 21.90% of the stock of PAVmed is held by insiders.Percentage Held by InstitutionsOnly 5.41% of the stock of PAVmed is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of PAVmed is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PAVmed is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.22 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PAVM Previous Symbol CUSIPN/A CIK1624326 Webwww.pavmed.com Phone212-949-4319Debt Debt-to-Equity RatioN/A Current Ratio0.36 Quick Ratio0.36Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.18) per share Price / Book-11.22Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-16,460,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-191.38%Miscellaneous Employees9 Outstanding Shares47,463,000Market Cap$95.88 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable NASDAQ:PAVM Rates by TradingView Receive PAVM News and Ratings via Email Sign-up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter. PAVmed (NASDAQ:PAVM) Frequently Asked Questions How has PAVmed's stock been impacted by COVID-19 (Coronavirus)? PAVmed's stock was trading at $1.74 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PAVM stock has increased by 16.1% and is now trading at $2.02. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of PAVmed? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PAVmed. When is PAVmed's next earnings date? PAVmed is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for PAVmed. How were PAVmed's earnings last quarter? PAVmed Inc (NASDAQ:PAVM) released its quarterly earnings results on Thursday, May, 21st. The company reported ($0.10) EPS for the quarter. View PAVmed's earnings history. What price target have analysts set for PAVM? 1 equities research analysts have issued 1-year target prices for PAVmed's stock. Their forecasts range from $5.00 to $5.00. On average, they expect PAVmed's stock price to reach $5.00 in the next year. This suggests a possible upside of 147.5% from the stock's current price. View analysts' price targets for PAVmed. Has PAVmed been receiving favorable news coverage? News coverage about PAVM stock has trended extremely negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PAVmed earned a news sentiment score of -4.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the company's share price in the near term. View the latest news about PAVmed. Who are some of PAVmed's key competitors? Some companies that are related to PAVmed include AngioDynamics (ANGO), Cytosorbents (CTSO), Repro-Med Systems (REPR), Utah Medical Products (UTMD), Alphatec (ATEC), Iradimed (IRMD), SeaSpine (SPNE), Westaim (WEDXF), iCAD (ICAD), Pulse Biosciences (PLSE), RenovaCare (RCAR), Accuray (ARAY), Liquidia Technologies (LQDA), T2 Biosystems (TTOO) and Apyx Medical (APYX). View all competitors. What other stocks do shareholders of PAVmed own? Based on aggregate information from My MarketBeat watchlists, some companies that other PAVmed investors own include Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), AVEO Pharmaceuticals (AVEO), Opko Health (OPK), BioCryst Pharmaceuticals (BCRX), FuelCell Energy (FCEL) and Ibio (IBIO). Who are PAVmed's key executives? PAVmed's management team includes the following people: Dr. Lishan Aklog M.D., Chairman & CEO (Age 53)Mr. Dennis M. McGrath CPA, Pres, CFO & Sec. (Age 62)Dr. Brian J. deGuzman M.D., Chief Medical Officer (Age 54)Mike Havrilla, Director of Investor RelationsMr. Shaun M. O'Neil, Chief Commercial Officer What is PAVmed's stock symbol? PAVmed trades on the NASDAQ under the ticker symbol "PAVM." How do I buy shares of PAVmed? Shares of PAVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is PAVmed's stock price today? One share of PAVM stock can currently be purchased for approximately $2.02. How big of a company is PAVmed? PAVmed has a market capitalization of $95.88 million. PAVmed employs 9 workers across the globe. What is PAVmed's official website? The official website for PAVmed is www.pavmed.com. How can I contact PAVmed? PAVmed's mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The company can be reached via phone at 212-949-4319 or via email at [email protected] This page was last updated on 7/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
